Aifarui (Afatinib) 30mg Tablets | CSPC Ouyi China Generic | GLT

Generic Information: Aifarui (Afatinib) — CSPC Ouyi, China

Aifarui is a domestic Chinese generic of afatinib produced by CSPC Ouyi Pharmaceutical Co., Ltd., a subsidiary of the CSPC Pharmaceutical Group (Shijiazhuang Pharmaceutical Group), one of China's largest listed pharmaceutical enterprises. Supplied as 30 mg film-coated tablets in a 7-tablet strip, Aifarui provides the reduced-dose strength of the second-generation irreversible EGFR inhibitor. CSPC Ouyi received afatinib approval, with the product deemed to have passed the generic consistency evaluation.

What Is Aifarui (Afatinib) Used For?

Aifarui is used to treat non-small cell lung cancer with EGFR-activating mutations, including exon 19 deletions, the L858R substitution, and uncommon mutations such as G719X, L861Q and S768I. It is a first-line option for EGFR-mutant NSCLC and is also used in metastatic squamous NSCLC after progression on platinum-based chemotherapy. The 30 mg strength is commonly used for dose reduction or in patients with impaired renal function.

How Does Aifarui (Afatinib) Work?

Aifarui contains afatinib, an irreversible pan-ErbB tyrosine kinase inhibitor that covalently binds EGFR, HER2 and ErbB4, permanently blocking the growth signals that EGFR-mutant lung cancer cells depend on. This irreversible mechanism provides durable tumor control and extends to uncommon EGFR mutations, distinguishing afatinib from first-generation reversible inhibitors.

Indications

Aifarui is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer with non-resistant EGFR mutations, and for metastatic squamous NSCLC progressing on or after platinum-based therapy. EGFR mutation testing is required before treatment.

Dosage

The standard afatinib dose is 40 mg once daily; the 30 mg strength is used for severe renal impairment or dose reduction for tolerability. Aifarui 30 mg should be taken once daily on an empty stomach — at least one hour before or two hours after food. The 7-tablet strip is one week of therapy.

Side Effects

Common side effects of Aifarui include diarrhea, acneiform rash, stomatitis, paronychia, dry skin and decreased appetite. Serious reactions such as interstitial lung disease, hepatotoxicity and severe skin disorders are uncommon but require prompt medical attention. Proactive management of diarrhea and skin symptoms is recommended.

Storage

Store Aifarui in a cool, dry place away from sunlight and moisture, in its original packaging. Keep out of reach of children and swallow tablets whole with water.

Why Choose the GLT?

Aifarui through GLT offers a consistency-evaluated generic from the CSPC group in the 30 mg strength, ideal for patients who need a reduced dose or have kidney impairment. As a Hong Kong-licensed supplier, we source genuine stock and provide the documentation needed for confident purchasing. For those seeking an affordable, quality-assured 30 mg afatinib from a major listed pharmaceutical group, Aifarui is a strong choice.

How to Order Aifarui (Afatinib)

Contact us on WhatsApp at +86 15234153837 or by email at [email protected] to order. Share your quantity and destination, and we will confirm availability, pricing and delivery.

FAQ

Who makes Aifarui? Aifarui is produced by CSPC Ouyi Pharmaceutical Co., Ltd., a subsidiary of the CSPC Pharmaceutical Group, and received afatinib approval as a consistency-evaluated generic.

Why choose the 30 mg strength? The 30 mg dose is used for patients with severe renal impairment or when a dose reduction is needed to improve tolerability.

Is Aifarui equivalent to the originator? Yes, Aifarui was deemed to have passed the generic consistency evaluation, confirming bioequivalence to the originator afatinib.

Do I need a prescription? Yes, afatinib is a prescription oncology medicine used under physician supervision.